share_log

ALT5 Sigma Reports 114% Year-Over-Year Increase in Transaction Volume for the Month of July 2024

ALT5 Sigma Reports 114% Year-Over-Year Increase in Transaction Volume for the Month of July 2024

ALT5 Sigma报告,2024年7月交易成交量同比增长114%
Accesswire ·  08/13 08:30

LAS VEGAS, NV / ACCESSWIRE / August 13, 2024 / ALT5 Sigma Corporation (NASDAQ:ALTS), a fintech, providing next generation blockchain-powered technologies for tokenization, trading, clearing, settlement, payment, and safe-keeping of digital assets, released its transaction volume for July 2024.

ALT5 Sigma公司(NASDAQ: ALTS)是一家金融科技公司,提供下一代基于区块链技术的数字资产代币化、交易、清算、结算、支付和保管等服务。该公司宣布公布2024年7月的交易额,为1.795亿美元,同比增长114%,高于2023年7月的8400万美元。ALT5年至今的交易额为10.5亿美元,同比增长101%。

According to the company, ALT5's transaction volume exceeded US$179 million for the month of July 2024, which represents a year-over-year increase of 114% from the $84 million recorded in July 2023. ALT5's year-to-date transaction volume is $1.05 billion, which represents a year-over-year increase of 101%.

ALT5公司表示,截至2024年7月,ALT5的交易额超过1.79亿美元,同比增长114%,高于2023年7月的8400万美元。ALT5年至今的交易额为10.5亿美元,同比增长101%。

July 2024

July 2023

July 2022

July 2021

$179,352,052

$83,810,993

$47,264,497

$26,582,621

2024年7月

2023年7月

2022年7月

2021年7月

1.79352052亿美元

8381.0993万美元

4726.4497万美元

2658.2621万美元

"Based on historical seasonality that we have experienced over the last few years, the second half of the fiscal year traditionally sees an uptick in transaction volume. We are pleased with the year-over-year growth and encouraged by the month-over-month increase in business as well," said Vay Tham, Chief Revenue Officer of ALT5 Sigma Corporation. "We continue to focus on growth and providing our solutions to an expanding set of organizations in our core markets," further added Mr. Tham.

“基于我们在过去几年中所经历的历史季节性趋势,财年的下半年通常会看到交易量的上升。我们对同比增长感到高兴,并对业务的逐月增长感到鼓舞,”ALT5 Sigma公司的首席营收官Vay Tham说道。“我们继续专注于增长,并向我们的核心市场中越来越多的组织提供解决方案,”Tham先生补充道。

About ALT5 Sigma

关于ALT5 Sigma

The Company is a unique Nasdaq-listed multidisciplinary organization with a focus on healthcare and fintech. The Company is one of the constituents of the Russell Microcap Index, as of June 28, 2024.

该公司是一家独特的纳斯达克上市的多学科组织,专注于医疗保健和金融科技。截至2024年6月28日,该公司是罗素微型股指数的成分股之一。

Launched in 2018, ALT5 Sigma Inc. (a wholly-owned subsidiary of ALT5 Sigma Corporation) is a fintech company that provides next generation blockchain-powered technologies to enable a migration to a new global financial paradigm. ALT5 Sigma Inc., through its subsidiaries, offers two main platforms to its customers: "ALT5 Pay" and "ALT5 Prime". ALT5 Sigma Inc. processed over US$1.2 billion in cryptocurrency transactions in 2023.

ALT5 Sigma Inc.成立于2018年,是 ALT5 Sigma Corporation 的全资子公司,是一家提供区块链技术的金融科技公司,以实现迁移到一个新的全球金融范式为目标。ALT5 Sigma Inc.通过其子公司向客户提供两个主要平台:“ALT5 Pay”和“ALT5 Prime”。ALT5 Sigma Inc.在2023年的加密货币交易额超过12亿美元。

ALT5 Pay is a crypto-currency payment gateway that enables registered and approved global merchants to accept and make crypto-currency payments or to integrate the ALT5 Pay payment platform into their application or operations using the plugin with WooCommerce and or ALT5 Pay's checkout widgets and APIs. Merchants have the option to convert to fiat currency (s) automatically or to receive their payment in digital assets.

ALT5 Pay是一种加密货币支付网关,可以使全球注册和批准的商家接受和进行加密货币支付,或使用WooCommerce的插件或ALT5 Pay的结帐小部件和API集成ALT5 Pay支付平台到其应用程序或操作中。商家可以选择自动转换成法定货币或以数字资产接收付款。

ALT5 Prime is an electronic over-the-counter trading platform that enables registered and approved customers to buy and sell digital assets. Customers can purchase digital assets with fiat and, equally, can sell digital assets and receive fiat. ALT5 Prime is available through a browser-based access mobile phone application named "ALT5 Pro" that can be downloaded from the Apple App Store, from Google Play, through ALT5 Prime's FIX API, as well as through Broadridge Financial Solutions' NYFIX gateway for approved customers.

ALT5 Prime是一种电子场外交易平台,允许注册和批准的客户买卖数字资产。客户可以使用法定货币购买数字资产,同样,客户也可以出售数字资产并获得法定货币。ALT5 Prime可通过一个名为“ALT5 Pro”的基于浏览器的移动应用程序使用,该应用程序可从Apple App Store、Google Play、ALT5 Prime的FIX API以及Broadridge Financial Solutions的NYFIX网关中下载,并提供给批准的客户。

Through its biotech activities, the Company is developing innovative, actionable solutions intended to help end the opioid crisis. The Company is dedicated to funding resources toward innovation, technology, and education to find a key resolution to the national opioid epidemic, which is one of the deadliest and most widespread in the nation's history. Its drugs in the clinical trial pipeline have shown promise for their innovative targeting of the causes of pain as a strategic option for physicians averse to exposing patients to addictive opioids.

通过其生物科技业务,公司正在开发创新的、切实可行的解决方案,以帮助终结鸦片危机。该公司致力于向创新、技术和教育方面提供资金,以寻找国家历史上最致命和最普遍的鸦片流行病的关键解决方案。该公司在临床试验流水线中的药物已经显示出有希望将针对疼痛原因的创新治疗作为对不愿暴露于上瘾的鸦片类药物的患者的一种战略性选择。

Forward Looking Statements

前瞻性声明

This press release contains statements that are forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to the profitability and prospective growth of ALT5's platforms and business, that may include, but are not limited to, international currency risks, third-party or customer credit risks, liability claims stemming from ALT5's services, and technology challenges for future growth or expansion. This press release also contains statements and links relating to risks that JAN 101 will treat PAD, that JAN 123 will treat CRPS, the timing of the commencement of clinical trials, that the FDA will permit approval through a 505(b)(2) pathway for JAN 123, that upon approval JAN 101 will immediately disrupt the PAD market, and other statements, including words such as "continue", "expect", "intend", "will", "hope", "should", "would", "may", "potential", and other similar expressions. Such statements reflect the Company's current view with respect to future events, are subject to risks and uncertainties, and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by the Company, are inherently subject to significant business, economic, competitive, political, and social uncertainties, and contingencies.

本新闻稿包含作为1995年《私人证券诉讼改革法》定义的前瞻性陈述,包括但不限于涉及ALT5平台和业务的盈利能力和前景的声明,可能包括但不限于国际货币风险、第三方或客户信用风险、源于ALT5服务的责任索赔和未来增长或扩张的技术挑战。本新闻稿还包含涉及JAN 101将治疗PAD、JAN 123将治疗CRPS、临床试验开始时间、FDA将允许通过505(b)(2)途径批准JAN 123、获批后JAN 101将立即颠覆PAD市场以及其他声明,包括"继续"、"期望"、"打算"、"将"、"希望"、"应该"、"将"、"可能"、"潜在"等类似表述。这些陈述反映了公司对未来事件的当前看法,受到风险和不确定性的影响,必须基于公司认为合理但固有的业务、经济、竞争、政治和社会不确定性和 contingencies 的估计和假设。

Many factors could cause the Company's actual results, performance, or achievements to be materially different from any future results, performance or achievements described in this press release. Such factors could include, among others, those detailed in the Company's periodic reports filed with the Securities and Exchange Commission (the "SEC"). Should one or more of these risks or uncertainties materialize, or should the assumptions set out in the section entitled "Risk Factors" in the Company's filings with the SEC underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this press release and the Company does not intend, and does not assume any obligation, to update these forward-looking statements, except as required by law. The Company cannot assure that such statements will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Individuals are cautioned that forward-looking statements are not guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein.

许多因素可能导致公司的实际结果、绩效或成就与本新闻稿所描述的任何未来结果、绩效或成就有实质性不同。这些因素可能包括公司在美国证券交易委员会(SEC)提交的定期报告中详细描述的那些因素。如果其中一个或多个风险或不确定性成为现实,或者在公司提交给SEC的文件中“风险因素”部分所列的假设被证明不正确,实际结果可能与此处所述有所不同。这些前瞻性陈述是基于本新闻稿的日期进行的,公司无意义且无义务更新这些前瞻性陈述,除非法律要求。公司无法保证这些陈述将证明是准确的,因为实际结果和未来事件可能会与其中预期的有所不同。由于前瞻性陈述具有固有的不确定性,因此警告个人不要因难以确定的不确定性而对前瞻性陈述产生过度的依赖。

Media Contact Investor Relations

媒体联系投资者关系

IR@alt5sigma.com
1-800-400-2247
Contact Information

IR@alt5sigma.com
1-800-400-2247
联系信息

Investor Relations
Investor Relations
ir@alt5sigma.com
1-800-400-2247

投资者关系
投资者关系
ir@alt5sigma.com
1-800-400-2247

SOURCE: ALT 5 Sigma Corp.

SOURCE: ALT 5 Sigma Corp.


声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发